Allergan Sues Sun, Aurobindo, Zydus to Block Copies of Vraylar

Allergan said Sun Pharma, Aurobindo and Zydus Cadila have proposed a generic version of Vraylar, a treatment for schizophrenia and bipolar depression, that would violate two patents for the drug.

• Allergan is seeking a court order blocking copies until the patents have expired, and to collect cash compensation if copies are made before then, according to complaint filed Friday in federal court in Wilmington, Delaware
• Gedeon Richter, based in Budapest, Hungary, owns the patents, and Allergan’s Forest unit is the exclusive licensee, complaint says
• Patents expire in December 2028 and September 2029, supplemental filing says
• Vraylar had U.S. ...